A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis

Grants and Contracts Details

StatusFinished
Effective start/end date2/6/08 → 1/31/10

Funding

  • AstraZeneca Pharmaceuticals AB: $280,851.00